DaltonTx Expanded AI Platform for Antibody Discovery
The company upgraded its engine to process tens of thousands of antibody structures per hour for research teams.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Do you trust that using AI for drug discovery will lead to better medical treatments?
DaltonTx has expanded its artificial intelligence platform to support the discovery and design of complex antibody structures. The company also entered into a research partnership with the University of Oxford to facilitate antibody analysis.
Why it matters
The platform integration aims to streamline the drug development process by helping scientists predict and select the most viable antibody formats for experimental progression.
The engine processes up to 87,000 antibody structures per hour and supports multispecific, biparatopic, single-domain antibodies, and antibody-drug conjugates. The system integrates a real-time chat interface for technical troubleshooting.
The players
DaltonTx
This biotechnology company develops artificial intelligence platforms designed to accelerate the discovery and development of new therapeutic modalities.
University of Oxford
This historic research university is collaborating with DaltonTx on scientific research regarding antibody analysis.
Bonito Biosciences
This biotechnology firm entered a partnership with DaltonTx earlier this year to focus on the development of oligo therapies.
The details
The platform combines proprietary experimental data with AI-generated outputs to predict structural success. A specialized decision engine connects computational models with project data to guide researchers on which molecules to advance.
Timeline
June 2026: DaltonTx initially launched its AI platform.
Earlier this year: The company formed a partnership with Bonito Biosciences for oligo therapies.
October 2026: DaltonTx announced the expansion of its AI platform capabilities.
The Tech Race
The expansion of the Dalton engine AI architecture reflects the broader industry shift toward using generative modeling to collapse the time required for early-stage drug discovery. By moving beyond simple molecule design to complex modalities, the company aims to replace legacy trial-and-error laboratory methods with predictive computation.
The development of these AI tools may accelerate the speed at which novel antibody-based treatments move through the research pipeline toward clinical trials. For researchers and developers, the platform provides a new decision-support workflow that reduces manual analysis time.
The takeaway
Artificial intelligence is increasingly being utilized to predict the success of complex biological structures before physical lab testing begins. Researchers can leverage these computational tools to focus resources on the most promising drug candidates earlier in the development lifecycle.
Further reading
Learn more about the latest industry trends in Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that using AI for drug discovery will lead to better medical treatments?
